Katherine Baker, MD, MMHC, of Tennessee Oncology, highlights the need for physician-payer collaboration to tackle challenges and drive innovation in specialty care.
Before the Institute for Value-Based Medicine® (IVBM) event held in partnership with Tennessee Oncology on August 22, Katherine Baker, MD, MMHC, listed innovations she thinks help make specialty care delivery easier and which challenges require innovative solutions. Additionally, Baker explained the importance of hearing the perspectives of physicians and payers on specialty value-based care.
Baker was a co-chair of the IVBM event. Next month, she will join Tennessee Oncology as a practicing medical oncologist and the medical director of value-based care.
This transcript has been lightly edited for clarity.
Transcript
Are there any particular innovations that help make specialty care delivery easier? If so, what?
One thing that I have learned as a result of discussions in preparing for the event tonight is that collaboration—both across health care systems, as well as between health care systems and payers—really can amplify the effect of innovation and entrepreneurship and health care. By breaking down silos and forging partnerships between different organizations, we can really capitalize on resources and bring together data sets and people to drive innovation and value-based care.
On the payer side of things, partnerships between health care organizations and payers really bring together the people that are experts in the operational success and financial success of value-based care initiatives. So, I think bringing all of those people together in collaboration can really help to forge the way for innovation in value-based care.
Currently, what are the most pressing challenges in specialty care delivery that require innovative solutions?
I think the biggest challenge in specialty care delivery that is going to require very innovative solutions, particularly in value-based care, is the complexity of the conditions that we treat.
From the constant change in treatment pathways to personalized medicine that can vary from disease states, thinking about how we can both wrap payment and quality metrics around these complex conditions I think is really challenging and going to require some disruptive efforts in the field to be able to accomplish.
Why is it important to hear both physician and payer perspectives on specialty value-based care?
I think physicians and payers bring different perspectives to value-based care. On the physician side of things, they bring clinical expertise. It's important to have physicians be part of the conversations around value-based care because they can help to design metrics that really focus on the clinical outcomes that matter for both patients and health care providers.
On the payer side of things, as I previously mentioned, I think they bring the operational and financial expertise to make value-based care payment models work. So, you really need collaboration between both of these 2 groups of people to be able to successfully implement patient-centric value-based care models.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More